Low-dose hydrocortisone in extremely preterm infants - Authors' reply

Affiliations

¹ Neonatal Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, CHU Robert Debré, Université Paris Diderot, Sorbone Paris Cité, INSERM U1141, Paris, France. Electronic address: olivier.baud@rdb.aphp.fr.
² Unit of Clinical Epidemiology, Assistance Publique-Hôpitaux de Paris, CHU Robert Debré, Université Paris Diderot, Sorbonne Paris-Cité, INSERM U1123 and CIC-EC 1426, Paris, France.
³ Department of Pediatrics and Neonatology, University of New Mexico School of Medicine, Albuquerque, NM, USA.

Comment

Olivier Baud et al. Lancet. 2016.

. 2016 Sep 17;388(10050):1158-9.

doi: 10.1016/S0140-6736(16)31611-7. Epub 2016 Sep 16.

¹ Neonatal Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, CHU Robert Debré, Université Paris Diderot, Sorbone Paris Cité, INSERM U1141, Paris, France. Electronic address: olivier.baud@rdb.aphp.fr.
² Unit of Clinical Epidemiology, Assistance Publique-Hôpitaux de Paris, CHU Robert Debré, Université Paris Diderot, Sorbonne Paris-Cité, INSERM U1123 and CIC-EC 1426, Paris, France.
³ Department of Pediatrics and Neonatology, University of New Mexico School of Medicine, Albuquerque, NM, USA.

No abstract available

Comment on

Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial.
Baud O, Maury L, Lebail F, Ramful D, El Moussawi F, Nicaise C, Zupan-Simunek V, Coursol A, Beuchée A, Bolot P, Andrini P, Mohamed D, Alberti C; PREMILOC trial study group. Baud O, et al. Lancet. 2016 Apr 30;387(10030):1827-36. doi: 10.1016/S0140-6736(16)00202-6. Epub 2016 Feb 23. Lancet. 2016. PMID: 26916176 Clinical Trial.